Alkermes (ALKS) Intangibles (2011 - 2026)

Alkermes (ALKS) posted quarterly Intangibles of $1.8 billion for Q2 2026, little changed quarter-over-quarter from $1.8 billion in Q1 2026.

Alkermes (ALKS) Intangibles (2011 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Intangibles for 16 consecutive years, with $1.8 billion the latest figure, recorded in Q2 2026.

In Q2 2026, Intangibles changed N/A year-over-year to $1.8 billion; the TTM figure through Jun 2026 stood at $1.8 billion (changed N/A YoY), while the FY2025 annual figure was $815000.0, changed N/A from the prior year.
Intangibles held at $1.8 billion in Q2 2026 per ALKS's latest filing, from $1.8 billion in the prior quarter.
Across five years, Intangibles topped out at $1.8 billion in Q1 2026 and bottomed at $815000.0 in Q4 2025.
Historically, Intangibles has averaged $688.7 million across 5 years, with a median of $583.8 million in 2022.
Annual changes were most pronounced in 2022 — Intangibles rose 0.17% — and 2023, when it plunged 99.66%.
Alkermes' Intangibles stood at $583.8 million in 2022, then slumped by 99.66% to $2.0 million in 2023, then surged by 29219.44% to $583.8 million in 2024, then slumped by 99.86% to $815000.0 in 2025, then surged by 220255.83% to $1.8 billion in 2026.
Business Quant data shows ALKS's Intangibles at $1.8 billion in Q2 2026, $1.8 billion in Q1 2026, and $815000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Haleon	43.85 Bn	42.88 Bn	-	-
2	Teva Pharmaceutical Industries	43.02 Bn	39.37 Bn	2.15 Bn	3.45 Bn
3	Zoetis	31.47 Bn	29.79 Bn	1.05 Bn	918.00 Mn
4	Takeda Pharmaceutical	28.59 Bn	22.79 Bn	5.10 Bn	21.28 Bn
5	United Therapeutics	22.20 Bn	19.53 Bn	683.80 Mn	-
6	Viatris	18.76 Bn	17.87 Bn	1.46 Bn	13.68 Bn
7	Neurocrine Biosciences	15.45 Bn	15.06 Bn	935.80 Mn	2.23 Bn
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	3.20 Bn
9	Dr Reddys Laboratories	10.10 Bn	9.94 Bn	-	1.12 Bn
10	Alkermes	8.07 Bn	7.42 Bn	397.90 Mn	1.80 Bn

Download Data